(Q38037488)

27 August 2017

The evolving role of immunotherapy in prostate cancer (English)

1 reference

27 August 2017

1 reference

W R Gerritsen

1

1 reference

27 August 2017

1 September 2012

1 reference

27 August 2017

1 reference

27 August 2017

23 Suppl 8

1 reference

27 August 2017

viii22-7

1 reference

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

27 August 2017

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS259

Prostate cancer as a model for tumour immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS259

Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS259

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS259

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS259

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS259

Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS259

Vaccines against human carcinomas: strategies to improve antitumor immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS259

Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS259

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS259

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS259

Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS259

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS259

Improved endpoints for cancer immunotherapy trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS259

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS259

Pox viral vaccine approaches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS259

Prostate cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS259

Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS259

Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS259

A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS259

Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS259

Cellular vaccine approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS259

Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS259

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS259

Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS259

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDS259

1 reference

27 August 2017

1 reference

PubMed ID

22918924